Literature DB >> 19052752

Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis.

Shilpi Agarwal1, Ramnath Misra, Amita Aggarwal.   

Abstract

In chronic arthritis cartilage and bone destruction occur as a consequence of synovial inflammation. It is mainly mediated by matrix metalloproteinases and RANKL-OPG pathways. Data on synovial fluid levels of these mediators in enthesitis related arthritis subtype (ERA) of JIA are not available. MMP-1, MMP-3, TIMP, sRANKL and OPG levels were measured in synovial fluid from patients with ERA and compared with other arthritides, polyarticular (Poly) JIA, RA and osteoarthritis (OA). sRANKL was detectable in 25/41 of ERA patients, 4/16 of Poly JIA patients. Median SF sRANKL level in patients with ERA was higher as compared to OA (p < 0.001) and poly JIA (p < 0.05) but were comparable to RA. The median OPG level in ERA was lower as compared to OA (p < 0.001), comparable to RA but was higher than poly JIA (p < 0.001). sRANKL/OPG ratio was significantly higher in ERA and Poly JIA compared to OA (p < 0.0001, p < 0.0001 respectively). The median MMP3 levels in ERA (74 microg/ml) was lower as compared to poly JIA (410 microg/ml; p < 0.0001) and RA (340 ug/ml; p < 0.0001) but was comparable to OA (107 microg/ml). The median level of ProMMP1 in ERA (0.70 microg/ml) was lower as compared to RA (2.9 microg/ml; p < 0.0001) and poly JIA but was elevated as compared to OA patients (0.1 microg/ml; p < 0.0001). TIMP1 levels in ERA were higher than poly JIA and RA patients. MMP3/TIMP1 ratio was lower in ERA compared to polyarticular JIA patients (p < 0.05). Ours is the first study reporting elevated sRANKL and reduced OPG levels and elevated sRANKL/OPG ratio in SF of children with JIA resulting in a mileu associated with bone loss. In addition, ERA patients had lower MMP level as well as MMP/TIMP ratio as compared to poly JIA which may partly explain lesser degree of joint damage seen in ERA as compared to poly JIA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19052752     DOI: 10.1007/s00296-008-0805-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  18 in total

1.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.

Authors:  Y Yoshihara; H Nakamura; K Obata; H Yamada; T Hayakawa; K Fujikawa; Y Okada
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Inflammation in juvenile idiopathic arthritis.

Authors:  Kathleen E Sullivan
Journal:  Pediatr Clin North Am       Date:  2005-04       Impact factor: 3.278

3.  Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.

Authors:  R E Petty; T R Southwood; J Baum; E Bhettay; D N Glass; P Manners; J Maldonado-Cocco; M Suarez-Almazor; J Orozco-Alcala; A M Prieur
Journal:  J Rheumatol       Date:  1998-10       Impact factor: 4.666

4.  Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study.

Authors:  N J Peake; K Khawaja; A Myers; D Jones; T E Cawston; A D Rowan; H E Foster
Journal:  Rheumatology (Oxford)       Date:  2005-07-27       Impact factor: 7.580

5.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

Authors:  N Bucay; I Sarosi; C R Dunstan; S Morony; J Tarpley; C Capparelli; S Scully; H L Tan; W Xu; D L Lacey; W J Boyle; W S Simonet
Journal:  Genes Dev       Date:  1998-05-01       Impact factor: 11.361

6.  Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis.

Authors:  M Skoumal; G Kolarz; G Haberhauer; W Woloszczuk; G Hawa; A Klingler
Journal:  Rheumatol Int       Date:  2005-05-12       Impact factor: 2.631

7.  Serum and synovial fluid concentrations of matrix metalloproteinases 3 and its tissue inhibitor 1 in juvenile idiopathic arthritides.

Authors:  Marco Gattorno; Silvia Vignola; Fernanda Falcini; Federica Sabatini; Antonella Buoncompagni; Gabriele Simonini; Paolo Picco; Vito Pistoia
Journal:  J Rheumatol       Date:  2002-04       Impact factor: 4.666

8.  Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.

Authors:  G Keyszer; I Lambiri; R Nagel; C Keysser; M Keysser; E Gromnica-Ihle; J Franz; G R Burmester; K Jung
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

9.  Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis.

Authors:  Pradip Kumar Sarma; Ramnath Misra; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2007-08-17       Impact factor: 2.980

10.  Synovial membrane expression of matrix metalloproteinases and tissue inhibitor 1 in juvenile idiopathic arthritides.

Authors:  Marco Gattorno; Valeria Gerloni; Adriana Morando; Federico Comanducci; Antonella Buoncompagni; Paolo Picco; Flavio Fantini; Vito Pistoia; Claudio Gambini
Journal:  J Rheumatol       Date:  2002-08       Impact factor: 4.666

View more
  10 in total

1.  Influence of Periostin on Synoviocytes in Knee Osteoarthritis.

Authors:  Yutaro Tajika; Tatsuya Moue; Shintaro Ishikawa; Kazuhito Asano; Takayuki Okumo; Hiroshi Takagi; Tadashi Hisamitsu
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

2.  Featured Article: Nanoenhanced matrix metalloproteinase-responsive delivery vehicles for disease resolution and imaging.

Authors:  Donald A McCarthy; Ahmad A Nazem; James McNeilan; Nicole L Shakerley; Ryan R Clark; María D Idelchik; Mehmet Yigit; J Andrés Melendez
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-29

Review 3.  Cytokine overproduction, T-cell activation, and defective T-regulatory functions promote nephritis in systemic lupus erythematosus.

Authors:  Marco Tucci; Stefania Stucci; Sabino Strippoli; Francesco Silvestris
Journal:  J Biomed Biotechnol       Date:  2010-06-29

4.  Secondary osteoporosis in patients with juvenile idiopathic arthritis.

Authors:  Kristyna Brabnikova Maresova
Journal:  J Osteoporos       Date:  2011-02-20

5.  Secretion of pro-inflammatory cytokines and chemokines and loss of regulatory signals by fibroblast-like synoviocytes in juvenile idiopathic arthritis.

Authors:  AnneMarie C Brescia; Megan M Simonds; Kathleen E Sullivan; Carlos D Rose
Journal:  Proteomics Clin Appl       Date:  2017-01-17       Impact factor: 3.494

Review 6.  Alterations of Extracellular Matrix Components in the Course of Juvenile Idiopathic Arthritis.

Authors:  Magdalena Wojdas; Klaudia Dąbkowska; Katarzyna Winsz-Szczotka
Journal:  Metabolites       Date:  2021-02-25

Review 7.  B Cells on the Stage of Inflammation in Juvenile Idiopathic Arthritis: Leading or Supporting Actors in Disease Pathogenesis?

Authors:  Rita A Moura; João Eurico Fonseca
Journal:  Front Med (Lausanne)       Date:  2022-04-04

8.  GAAGs, COMP, and YKL-40 as Potential Markers of Cartilage Turnover in Blood of Children with Juvenile Idiopathic Arthritis Treated with Etanercept-Relationship with ADAMTS4, ADAMTS5, and PDGF-BB.

Authors:  Klaudia Dąbkowska; Magdalena Wojdas; Kornelia Kuźnik-Trocha; Grzegorz Wisowski; Anna Gruenpeter; Katarzyna Komosińska-Vassev; Krystyna Olczyk; Katarzyna Winsz-Szczotka
Journal:  J Clin Med       Date:  2022-08-29       Impact factor: 4.964

9.  Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.

Authors:  Kristyna Brabnikova-Maresova; Katerina Jarosova; Karel Pavelka; Jan J Stepan
Journal:  Arthritis Res Ther       Date:  2014-10-04       Impact factor: 5.156

Review 10.  Osteoimmunology: A Current Update of the Interplay Between Bone and the Immune System.

Authors:  Christian Guder; Sascha Gravius; Christof Burger; Dieter C Wirtz; Frank A Schildberg
Journal:  Front Immunol       Date:  2020-01-31       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.